Takhzyro Prefilled Syringe Now Available for Patients With Hereditary Angioedema
The prefilled syringe is provided as a 300mg/2mL (150mg/mL) ready-to-use solution for subcutaneous injection and does not require additional reconstitution or dilution.
Hereditary Angioedema
FDA Approves Berinert Administration Kit for Hereditary Angioedema
The FDA has approved the supplemental request for the co-packaging of a convenience administration kit for Berinert (C1 esterase inhibitor, [Human]) for acute abdominal, facial, or laryngeal attacks of hereditary angioedema.
Berotralstat May Reduce On-Demand Medication Use in Hereditary Angioedema
Berotralstat may reduce the use of on-demand medications in patients with hereditary angioedema (HAE) who were previously treated with prophylactic therapies.
Oral Hereditary Angioedema Treatment Provides Effective Bradykinin-Inhibiting Concentrations
A single dose of PHA-022121, an oral beta-2 antagonist, was associated with effective bradykinin-inhibiting concentrations within 15 minutes of administration in patients with hereditary angioedema.
New Drug Product: Orladeyo
This slideshow shows drug information for Orladeyo. Click here for the complete Orladeyo monograph.
Orladeyo Now Available for Hereditary Angioedema
The oral, once-daily treatment will be shipped to patients with a prescription by specialty pharmacy Optime Care, Inc.
FDA Approves Orladeyo to Prevent Hereditary Angioedema Attacks
Orladeyo works by binding to plasma kallikrein and inhibiting its proteolytic activity.
Lanadelumab Markedly Reduces Hereditary Angioedema Attacks Over 30-Month Period
Lanadelumab was effective for reducing hereditary angioedema attacks at up to 30 weeks of treatment, suggesting the monoclonal antibody is associated with sustained long-term efficacy.
Berotralstat Improves Quality of Life in Hereditary Angioedema
Patients with hereditary angioedema taking berotralstat prophylactically had improved quality of life.
Haegarda Approved for Pediatric Hereditary Angioedema
The expanded approval was based on data from the pivotal phase 3 COMPACT study and the COMPACT open-label extension study.
